Keratitis - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H1 2017, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Keratitis - Overview
Keratitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Keratitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Keratitis - Companies Involved in Therapeutics Development
Adamis Pharmaceuticals Corp
Dompe Farmaceutici SpA
Editas Medicine Inc
EyeGate Pharmaceuticals Inc
NanoViricides Inc
RegeneRx Biopharmaceuticals Inc
SIFI SpA
The Medicines Company
Keratitis - Drug Profiles
acyclovir sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-2088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-31G - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenegermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Herpetic Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpecide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDE-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KU-55933 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PIM-45 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
polihexanide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGN-259 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Neurotrophic Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DNA Synthesis for Herpetic Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
targocil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tigecycline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Keratitis - Dormant Projects
Keratitis - Discontinued Products
Keratitis - Product Development Milestones
Featured News & Press Releases
Dec 12, 2016: EMA Validates the Marketing Authorisation Application for Cenegermin Eye Drops (Oxervate) Submitted by Dompe
Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China
May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease
Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday
Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials
Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial
Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259
Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
Sep 25, 2014: EuCornea: Dompe wins the "Best Poster Award" for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis
Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis
Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Keratitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Keratitis - Pipeline by Adamis Pharmaceuticals Corp, H1 2017
Keratitis - Pipeline by Dompe Farmaceutici SpA, H1 2017
Keratitis - Pipeline by Editas Medicine Inc, H1 2017
Keratitis - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
Keratitis - Pipeline by NanoViricides Inc, H1 2017
Keratitis - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
Keratitis - Pipeline by SIFI SpA, H1 2017
Keratitis - Pipeline by The Medicines Company, H1 2017
Keratitis - Dormant Projects, H1 2017
Keratitis - Discontinued Products, H1 2017